248 related articles for article (PubMed ID: 28100771)
1. Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.
Shi SY; Luk CT; Schroer SA; Kim MJ; Dodington DW; Sivasubramaniyam T; Lin L; Cai EP; Lu SY; Wagner KU; Bazinet RP; Woo M
J Biol Chem; 2017 Mar; 292(9):3789-3799. PubMed ID: 28100771
[TBL] [Abstract][Full Text] [Related]
2. Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma.
Corbit KC; Wilson CG; Lowe D; Tran JL; Vera NB; Clasquin M; Mattis AN; Weiss EJ
JCI Insight; 2019 Aug; 5(17):. PubMed ID: 31393852
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance.
Shi SY; Martin RG; Duncan RE; Choi D; Lu SY; Schroer SA; Cai EP; Luk CT; Hopperton KE; Domenichiello AF; Tang C; Naples M; Dekker MJ; Giacca A; Adeli K; Wagner KU; Bazinet RP; Woo M
J Biol Chem; 2012 Mar; 287(13):10277-10288. PubMed ID: 22275361
[TBL] [Abstract][Full Text] [Related]
4. Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression.
Kaltenecker D; Themanns M; Mueller KM; Spirk K; Suske T; Merkel O; Kenner L; Luís A; Kozlov A; Haybaeck J; Müller M; Han X; Moriggl R
Cytokine; 2019 Dec; 124():154569. PubMed ID: 30389231
[TBL] [Abstract][Full Text] [Related]
5. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
[TBL] [Abstract][Full Text] [Related]
6. NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition.
Vesting AJ; Jais A; Klemm P; Steuernagel L; Wienand P; Fog-Tonnesen M; Hvid H; Schumacher AL; Kukat C; Nolte H; Georgomanolis T; Altmüller J; Pasparakis M; Schmidt A; Krüger M; Supprian MS; Waisman A; Straub BK; Raschzok N; Bernier M; Birkenfeld AL; Hövelmeyer N; Brüning JC; Wunderlich FT
Mol Metab; 2022 Dec; 66():101626. PubMed ID: 36356831
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
8. Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma.
Kessler SM; Simon Y; Gemperlein K; Gianmoena K; Cadenas C; Zimmer V; Pokorny J; Barghash A; Helms V; van Rooijen N; Bohle RM; Lammert F; Hengstler JG; Mueller R; Haybaeck J; Kiemer AK
Int J Mol Sci; 2014 Apr; 15(4):5762-73. PubMed ID: 24714086
[TBL] [Abstract][Full Text] [Related]
9. NLRC3 silencing accelerates the invasion of hepatocellular carcinoma cell via IL-6/JAK2/STAT3 pathway activation.
Kang JH; Li MJ; Luan PP; Jiang DK; Chen YW; Xu X; Yu Q; Xu YW; Su Q; Peng WH; Jian WX
Cell Biol Int; 2020 Oct; 44(10):2053-2064. PubMed ID: 32584509
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice.
Themanns M; Mueller KM; Kessler SM; Golob-Schwarzl N; Mohr T; Kaltenecker D; Bourgeais J; Paier-Pourani J; Friedbichler K; Schneller D; Schlederer M; Zebedin-Brandl E; Terracciano LM; Han X; Kenner L; Wagner KU; Mikulits W; Kozlov AV; Heim MH; Gouilleux F; Haybaeck J; Moriggl R
Sci Rep; 2016 Oct; 6():34719. PubMed ID: 27713471
[TBL] [Abstract][Full Text] [Related]
11. Kefir peptides prevent high-fructose corn syrup-induced non-alcoholic fatty liver disease in a murine model by modulation of inflammation and the JAK2 signaling pathway.
Chen HL; Tsai TC; Tsai YC; Liao JW; Yen CC; Chen CM
Nutr Diabetes; 2016 Dec; 6(12):e237. PubMed ID: 27941940
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice.
Jung KH; Yoo W; Stevenson HL; Deshpande D; Shen H; Gagea M; Yoo SY; Wang J; Eckols TK; Bharadwaj U; Tweardy DJ; Beretta L
Clin Cancer Res; 2017 Sep; 23(18):5537-5546. PubMed ID: 28533225
[No Abstract] [Full Text] [Related]
13. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
14. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis.
He F; Zhang P; Liu J; Wang R; Kaufman RJ; Yaden BC; Karin M
J Hepatol; 2023 Aug; 79(2):362-377. PubMed ID: 36996941
[TBL] [Abstract][Full Text] [Related]
15. Hepatic loss of
Li X; Liu L; Li R; Wu A; Lu J; Wu Q; Jia J; Zhao M; Song H
J Biol Chem; 2018 Apr; 293(14):5160-5171. PubMed ID: 29475944
[TBL] [Abstract][Full Text] [Related]
16. Adipocyte JAK2 Regulates Hepatic Insulin Sensitivity Independently of Body Composition, Liver Lipid Content, and Hepatic Insulin Signaling.
Corbit KC; Camporez JPG; Edmunds LR; Tran JL; Vera NB; Erion DM; Deo RC; Perry RJ; Shulman GI; Jurczak MJ; Weiss EJ
Diabetes; 2018 Feb; 67(2):208-221. PubMed ID: 29203511
[TBL] [Abstract][Full Text] [Related]
17. p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice.
Tomita K; Teratani T; Suzuki T; Oshikawa T; Yokoyama H; Shimamura K; Nishiyama K; Mataki N; Irie R; Minamino T; Okada Y; Kurihara C; Ebinuma H; Saito H; Shimizu I; Yoshida Y; Hokari R; Sugiyama K; Hatsuse K; Yamamoto J; Kanai T; Miura S; Hibi T
J Hepatol; 2012 Oct; 57(4):837-43. PubMed ID: 22641095
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalchoholic fatty liver disease.
Vansaun MN; Mendonsa AM; Lee Gorden D
PLoS One; 2013; 8(9):e73054. PubMed ID: 24039859
[TBL] [Abstract][Full Text] [Related]
19. Deletion of HNF1α in hepatocytes results in fatty liver-related hepatocellular carcinoma in mice.
Ni Q; Ding K; Wang KQ; He J; Yin C; Shi J; Zhang X; Xie WF; Shi YQ
FEBS Lett; 2017 Jul; 591(13):1947-1957. PubMed ID: 28547778
[TBL] [Abstract][Full Text] [Related]
20. Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer.
Friedbichler K; Themanns M; Mueller KM; Schlederer M; Kornfeld JW; Terracciano LM; Kozlov AV; Haindl S; Kenner L; Kolbe T; Mueller M; Snibson KJ; Heim MH; Moriggl R
Hepatology; 2012 Mar; 55(3):941-52. PubMed ID: 22031092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
